The purpose of this study is to determine whether tifacogin is effective and safe in the treatment of patients with severe community-acquired pneumonia.
Official Title
Tifacogin (recombinant tissue factor pathway inhibitor) for the Treatment of Patients with Severe Community-Acquired Pneumonia
Conditions
Pneumonia
Study Type
Interventional
Study Design
Treatment
Further Details
Study Start
Eligibility & Criteria
Inclusion Criteria: * Diagnosis of community-acquired pneumonia supported by additional clincal, radiological, and microbiological evidence * Pneumonia of sufficient severity to require ICU admission and managementExclusion Criteria: * Pregnancy * Weight over 150 kg * Patients at increased risk of bleeding * Treatment with drotrecogin alfa or anticipated need for drotrecogin alfa * Treatment with heparin or anticipated need for heparin
Total Enrolment
Contact Details
Sites are available all over Australia, For information on a site near you, call 1-510-923-3222
All content and media on the HealthEngine Blog is created and published online for informational purposes only. It is not intended to be a substitute for professional medical advice and should not be relied on as health or personal advice. Always seek the guidance of your doctor or other qualified health professional with any questions you may have regarding your health or a medical condition. Never disregard the advice of a medical professional, or delay in seeking it because of something you have read on this Website. If you think you may have a medical emergency, call your doctor, go to the nearest hospital emergency department, or call the emergency services immediately.
Related Articles
Need a health appointment?
Find and book a doctor, dentist, physio and more on Healthengine
Find a practitioner
